Literature DB >> 23187634

Use of new treatment modalities for non-small cell lung cancer care in the Medicare population.

Michael T Vest1, Jeph Herrin2, Pamela R Soulos3, Roy H Decker4, Lynn Tanoue1, Gaetane Michaud1, Anthony W Kim5, Frank Detterbeck6, Daniel Morgensztern7, Cary P Gross8.   

Abstract

BACKGROUND: Many older patients with early stage non-small cell lung cancer (NSCLC) do not receive curative therapy. New surgical techniques and radiation therapy modalities, such as video-assisted thoracoscopic surgery (VATS), potentially allow more patients to receive treatment. The adoption of these techniques and their impact on access to cancer care among Medicare beneficiaries with stage I NSCLC are unknown.
METHODS: We used the Surveillance, Epidemiology and End Results-Medicare database to identify patients with stage I NSCLC diagnosed between 1998 and 2007. We assessed temporal trends and created hierarchical generalized linear models of the relationship between patient, clinical, and regional factors and type of treatment.
RESULTS: The sample comprised 13,458 patients with a mean age of 75.7 years. The proportion of patients not receiving any local treatment increased from 14.6% in 1998 to 18.3% in 2007. The overall use of surgical resection declined from 75.2% to 67.3% ( P , .001), although the proportion of patients undergoing VATS increased from 11.3% to 32.0%. Similarly, although the use of new radiation modalities increased from 0% to 5.2%, the overall use of radiation remained stable. The oldest patients were less likely to receive surgical vs no treatment (OR, 0.12; 95% CI, 0.09-0.16) and more likely to receive radiation vs surgery (OR, 13.61; 95% CI, 9.75-19.0).
CONCLUSION: From 1998 to 2007, the overall proportion of older patients with stage I NSCLC receiving curative local therapy decreased, despite the dissemination of newer, less-invasive forms of surgery and radiation.

Entities:  

Mesh:

Year:  2013        PMID: 23187634      PMCID: PMC3566996          DOI: 10.1378/chest.12-1149

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

Review 1.  Is video-assisted thoracic surgery lobectomy better? Quality of life considerations.

Authors:  Todd L Demmy; Chukwumere Nwogu
Journal:  Ann Thorac Surg       Date:  2008-02       Impact factor: 4.330

Review 2.  Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time?

Authors:  Millie Das; Mohamed H K Abdelmaksoud; Billy W Loo; Nishita Kothary
Journal:  Curr Treat Options Oncol       Date:  2010-06

Review 3.  ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent.

Authors:  Richard M Gewanter; Kenneth E Rosenzweig; Joe Yujiao Chang; Roy Decker; Sarita Dubey; Feng-Ming Kong; Brian E Lally; Corey J Langer; Hoon Ku Lee; Benjamin Movsas
Journal:  Curr Probl Cancer       Date:  2010 May-Jun       Impact factor: 3.187

4.  Thoroughness of mediastinal staging in stage IIIA non-small cell lung cancer.

Authors:  Michael T Vest; Lynn Tanoue; Pamela R Soulos; Anthony W Kim; Frank Detterbeck; Daniel Morgensztern; Cary P Gross
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

5.  Use of postmastectomy radiotherapy in older women.

Authors:  Benjamin D Smith; Bruce G Haffty; Grace L Smith; Arti Hurria; Thomas A Buchholz; Cary P Gross
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-08       Impact factor: 7.038

6.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

7.  Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition).

Authors:  Walter J Scott; John Howington; Steven Feigenberg; Benjamin Movsas; Katherine Pisters
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

8.  Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies.

Authors:  Sai-Hong Ignatius Ou; Jason A Zell
Journal:  J Thorac Oncol       Date:  2009-10       Impact factor: 15.609

Review 9.  Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy.

Authors:  Bryan A Whitson; Shawn S Groth; Susan J Duval; Scott J Swanson; Michael A Maddaus
Journal:  Ann Thorac Surg       Date:  2008-12       Impact factor: 4.330

Review 10.  A systematic review of the impact of stigma and nihilism on lung cancer outcomes.

Authors:  Suzanne K Chambers; Jeffrey Dunn; Stefano Occhipinti; Suzanne Hughes; Peter Baade; Sue Sinclair; Joanne Aitken; Pip Youl; Dianne L O'Connell
Journal:  BMC Cancer       Date:  2012-05-20       Impact factor: 4.430

View more
  10 in total

1.  Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Authors:  Katrina Woodford; Sashendra Senthi
Journal:  Transl Lung Cancer Res       Date:  2015-10

2.  Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada.

Authors:  Alexander V Louie; George B Rodrigues; David A Palma; Suresh Senan
Journal:  Oncologist       Date:  2014-06-20

3.  Dosimetric evaluation of compensator intensity modulation-based stereotactic body radiotherapy for Stage I non-small-cell lung cancer.

Authors:  Y Tajima; H Nakayama; T Itonaga; S Shiraishi; M Okubo; R Mikami; S Sugahara; K Tokuuye
Journal:  Br J Radiol       Date:  2015-05-21       Impact factor: 3.039

4.  Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.

Authors:  Thomas B Richards; S Jane Henley; Mary C Puckett; Hannah K Weir; Bin Huang; Thomas C Tucker; Claudia Allemani
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

Review 5.  SBRT in operable early stage lung cancer patients.

Authors:  Johannes Roesch; Nicolaus Andratschke; Matthias Guckenberger
Journal:  Transl Lung Cancer Res       Date:  2014-08

6.  Pulmonologist involvement, stage-specific treatment, and survival in adults with non-small cell lung cancer and chronic obstructive pulmonary disease.

Authors:  Janaki A Deepak; Xinyi Ng; Josephine Feliciano; Li Mao; Amy J Davidoff
Journal:  Ann Am Thorac Soc       Date:  2015-05

7.  Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer: a population-based study on recent developments.

Authors:  C Ostheimer; C Evers; F Palm; R Mikolajczyk; D Vordermark; Daniel Medenwald
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-06       Impact factor: 4.553

8.  The cost of cancer-related physician services to Medicare.

Authors:  Sean Maroongroge; Simon P Kim; Sarah Mougalian; Kimberly Johung; Roy H Decker; Pamela R Soulos; Jessica B Long; Cary P Gross; James B Yu
Journal:  Yale J Biol Med       Date:  2015-06-01

9.  Trends and costs of stereotactic body radiation therapy in metastatic non-small cell lung cancer.

Authors:  Nataniel H Lester-Coll; Joan Skelly; Pamela M Vacek; Brian L Sprague
Journal:  J Thorac Dis       Date:  2022-07       Impact factor: 3.005

10.  Treatment and Survival Disparities in the National Cancer Institute's Patterns of Care Study (1987-2017).

Authors:  Dolly C Penn; Melanie Baker; Ann M Geiger; Linda C Harlan
Journal:  Cancer Invest       Date:  2018-08-23       Impact factor: 2.368

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.